Biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), announced on Monday that it has received US Food and Drug Administration (FDA) approval for Gazyva (obinutuzumab) to treat adults with primary membranous nephropathy (pMN) at risk of disease progression, making it the first and only approved treatment for the condition.
The approval is based on Phase III MAJESTY trial results, which showed that 36.1% of patients receiving Gazyva achieved complete remission of proteinuria after two years, compared with 5.7% for tacrolimus. Overall remission rates were 50% and 12.9%, respectively, with no new safety signals identified.
Primary membranous nephropathy is a rare, chronic autoimmune disease that can cause irreversible kidney damage and progress to kidney failure.
This approval marks Gazyva's third FDA authorisation in immune-mediated kidney diseases, following previous approvals for idiopathic nephrotic syndrome and lupus nephritis. The FDA is also reviewing Gazyva for systemic lupus erythematosus, with a decision expected by December 2026, while a European regulatory decision is anticipated following a positive recommendation from the CHMP.
Breakthrough T1D and Walgreens Foundation join forces to support the type 1 diabetes community
Innovent Biologics presents preclinical data for IL-6/TL1A bispecific antibody IAR177
Traws Pharma reports final Phase 2a COVID-19 data and advances influenza programme
Shanton Pharma's SAP-001 receives EMA and FDA paediatric study waivers in hyperuricaemia
Ascletis announces submission of US IND application for oral obesity combination therapy
AstraZeneca acquires biotechnology company Omniose to strengthen vaccine capabilities
Medivir secures US patent protection for fostrox and lenvatinib combination until 2044
PharmaLogic to acquire CDMO business and manufacturing facility from Lantheus
Ribo submits European Clinical Trial Application for SR122 in mixed and severe dyslipidaemia
Spermosens and Genea agree IVF study of JUNO-Checked in Australia